drugset / Trial / NCT06765928

Selinexor Combined With Venetoclax Maintenance Therapy After Allo-HSCT

NCT06765928

Phase 2 Not yet recruiting 73 enrolled Ruijin Hospital
NaSingle-groupOpen-labelTreatment

Summary

A multicenter, single-arm clinical study of evaluate the efficacy and safety of selinexor combined with venetoclax as maintenance therapy following allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia patients.

Timeline

Start
2025-01-01
Primary completion
2026-01-01
Completion
2028-01-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Selinexor Other / unclassified
Subject Venetoclax Small molecule